FDA, FTC send warning letters to three CBD marketers for false medical claims

Breaking News Emails

Get breaking news alerts and special reports. The news and stories that matter, delivered weekday mornings.

By Shamard Charles, M.D.

The Food and Drug Administration and the Federal Trade Commission sent warning letters Tuesday to three companies that market CBD products, saying the companies are making false claims about treating diseases such as cancer and Alzheimer’s.

The agencies claim that three companies — Nutra Pure, PotNetwork Holdings, and Advanced Spine and Pain — are falsely advertising the effectiveness of supplements that contain cannabidiol, commonly known as CBD. The products are marketed under names such as “Hemp Oil,” “CBD Softgels,” “CBD for Dogs,” “Liquid Gold Gummies,” and “CBD Oil.” One company in particular — Nutra Pure — advertises that scientific research supports their claims that their CBD product is an effective anti-seizure medication.

“According to their advertisements, the products can effectively treat diseases, including cancer, Alzheimer’s disease, fibromyalgia, and ‘neuropsychiatric disorders,’” the FDA and FTC said jointly in a statement.

The letters instruct the companies to notify the FTC within 15 days of receipt of the letter of the specific action taken to address the agency’s concerns.

This is the first time the FDA and FTC have issued a joint warning letter together, but it’s not the first time the companies have cracked down on unfounded CBD claims. In 2017, the FDA warned four companies to stop making unproven claims that their cannabis-based hemp and marijuana products could treat cancer. Last year, the FDA issued a statement banning CBD in food products.

http://platform.twitter.com/widgets.js